Priority review for Pfizer, Eyetech AMD drug

October 2004
PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11
Market Research Report
The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new drug application on June 17, under the FDA's Fast Track designation. A review of Macugen by the FDA and its Dermatologic and Ophthalmic Drugs Advisory Committee is currently scheduled for August 27, 2004.


Related Articles

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • Pipeline.  // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p12 

    The article presents news from the pharmaceutical industry. Pfizer Inc. received a setback when the FDA classified its newly approved nerve pain drug Lyrica as a controlled substance, resulting in additional requirements for doctors and pharmacists. Pfizer had been counting on Lyrica to offset...

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • AMD: A Revolution In Therapy Begins. Rosenfeld, Philip // Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96 

    Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that...

  • Eyetech sales force to offer Pfizer's latanoprost.  // Ophthalmology Times;6/1/2003, Vol. 28 Issue 11, p4 

    Reports on the help offered by the sales force of Eyetech Pharmaceuticals Inc. to sell the latanoprost ophthalmic solution of Pfizer Inc. to ophthalmologists in the U.S.

  • New Drug Treats Age-Related Macular Degeneration.  // FDA Consumer;Mar/Apr2005, Vol. 39 Issue 2, p4 

    Announces the approval given by the U.S. Food and Drug Administration to the drug Macugen from Eyetech Pharmaceuticals Inc. and Pfizer Inc. to slow vision loss in people with wet age-related macular degeneration (AMD). Overview of the therapeutic application of the drug targeting vascular...

  • Eyetech confident about future of aptamers. Talsma, Julia // Ophthalmology Times;8/1/2005, Vol. 30 Issue 15, p6 

    Reports on the announcement of Eyetech Pharmaceuticals Inc. regarding the commercial success of the drug pegaptanib sodium injection (Macugen), its drug for treatment of neovascular age-related macular degeneration in the U.S. Revision made to the 2005 sales projections for the drug; Safety...

  • Changes in pegaptanib labeling prompted by adverse reactions. Charters, Lynda // Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8 

    The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics